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Available Cell Substrates
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Boddy, Dr. John C. Bell, Dr. Jean-Simon Diallo
The Problem
• There is a rising global demand for virus-
based vaccines and therapeutics
• Viruses need to be propagated in cells
• Innate cellular antiviral responses are a 
primary hurdle for efficient viral replication
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The solution: Viral Sensitizer 
Technology (VST)
Viral sensitizer technology (VST) encompasses a collection of 
small molecules identified by high-throughput screening that 
enhance viral growth in some cases up to over 1000-fold
Virus output using VSe1
Red  = Viral Growth $$ = over 1000-fold increase
Diallo JS et al. Mol Ther, 2010
Viral sensitizer compounds, through a variety of mechanisms, 
affect the innate cellular antiviral response in order to 
promote more efficient growth of attenuated viruses 
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Viral Sensitizer
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ISRE-Luciferase activity VSV∆51 titers
Viral sensitizers repress cellular antiviral response
Diallo JS et al. Mol Ther, 2010
VST represses cellular antiviral response
Diallo JS et al. Mol Ther, 2010
50+ year old method New method
CELL-BASED VACCINE MANUFACTURING
• Most vaccines are virus-based and many are poorly growing attenuated virus 
strains
• Production of several vaccines (eg. Influenza, MVA) is dominated by egg-based 
methods which have a number of issues 
• Producers are starting to move towards continuous cell-line based productions and 
chemically defined media
• Few cell lines are approved for vaccine manufacturing
• The innate antiviral response can limit the production of virus from cells, 
providing an opportunity for VST
VST APPLICATION: MODIFIED VACCINIA ANKARA (MVA)
• Modified Vaccinia Ankara (MVA) is a multi-application 
vaccine platform approved for smallpox vaccination and 
in Phase II/III evaluation for several indications including 
Malaria, HIV, Influenza, and Cancer  
• MVA is currently produced in eggs or egg-derived CEF 
cells.
• BHK21 cell line is the only continuous mammalian 
cell line that supports MVA production 
MVA 
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VST INCREASES YIELD OF MVA IN BHK21
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** P-Value:0.039
**
>10-fold increase in viral titers
** Average of four separate experiments in sextuplicate
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VST SUBSTANTIALLY IMPROVES MVA YIELDS COMPARED 
TO STANDARD METHODS AT ROLLER BOTTLE SCALE
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The AMES mutagenicity test
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VST does not increase frameshift deletion rate
MRM method for detection of 
VST in purified virus cultures
MRM is a sensitive mass spectrometry-based method that 
allows for specific detection of peptides or molecules even 
in complex mixtures
MRM method for detection of 
VST in purified virus cultures
We can easily detect MRM transition of purified VST (1ug)  
MRM method for detection of 
VST in purified virus cultures
MVA preparation spiked with VST => 
Compound is easily detected
VST-assisted MVA preparation 
flowthrough => No compound-associated 
MRM transition signal detected 
(background)
Conclusions
• VST can increase yields of MVA by 4.5X 
in CEF and > 10-fold in BHK21 cells
• VST activity is maintained at the roller 
bottle scale
• VST is not DNA reactive based on AMES 
tests
• MRM methodologies can be used to 
detect VST, which is absent from purified 
VST-assisted MVA cultures
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